Does Medicare Cover GLP-1 Drugs for Weight Loss? (2026)

Direct Answer: Does Medicare Cover GLP-1 Weight Loss Drugs?

No, for most Medicare beneficiaries in 2026. Federal law explicitly excludes anti-obesity drugs from Part D coverage. Two narrow exceptions apply: Wegovy is covered for established cardiovascular disease, and the Medicare GLP-1 Bridge Program (July 1 to December 31, 2027) covers select GLP-1s at a $50/month copay for eligible beneficiaries.

Why Medicare Doesn't Cover Weight-Loss Drugs (The Statute)

The Medicare Modernization Act of 2003 (MMA) created Part D but prohibited coverage of anti-obesity drugs and anorexiants. The prohibition lives in Social Security Act Section 1927(d)(2)(A). This is a categorical exclusion written into federal law, not a plan-level benefit decision. No Part D plan can cover weight-loss drugs unless Congress changes the statute or CMS issues a formal exception.

This means even if your doctor prescribes Wegovy or Zepbound specifically for weight loss, and even if your plan's formulary lists the drug, the statutory exclusion blocks coverage when the diagnosis is obesity alone. Ozempic and Mounjaro carry only diabetes FDA indications for Medicare purposes, so they are not covered for weight loss under any exception.

Exception 1: Wegovy for Cardiovascular Risk Reduction

In March 2024, the FDA approved a new indication for Wegovy (semaglutide 2.4 mg): reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease who also have overweight or obesity. CMS responded the same month, clarifying that this indication takes Wegovy outside the anti-obesity drug exclusion. The drug is now being prescribed for a cardiovascular purpose, not a weight-loss purpose.

To qualify under this exception, a Medicare beneficiary must have all three: (1) a confirmed diagnosis of established cardiovascular disease such as coronary artery disease, prior heart attack, or prior stroke; (2) a BMI of 27 or higher (overweight) or 30 or higher (obese); and (3) a prescription written specifically for MACE risk reduction. If prescribed only for weight loss in a patient with CVD, the exclusion still applies. Standard Part D cost-sharing applies to Wegovy under this exception.

Exception 2: Medicare GLP-1 Bridge Program (July 1, 2026 to December 31, 2027)

The Medicare GLP-1 Bridge Program is a temporary coverage period that runs from July 1, 2026 through December 31, 2027. It covers three specific brand-name GLP-1 medications for chronic weight management regardless of cardiovascular disease status: all formulations of Wegovy (injectable and oral), Zepbound KwikPen (tirzepatide), and Foundayo.

The flat beneficiary copay under the Bridge Program is $50 per month. This copay does NOT count toward the 2026 Part D out-of-pocket cap of $2,100. The program expires December 31, 2027, at which point coverage reverts to the pre-Bridge rules unless Congress acts. Notable exclusions from the Bridge Program: Ozempic (diabetes indication only, not approved for weight loss), Mounjaro (diabetes indication, not approved for weight loss), and Zepbound single-dose pen and single-dose vial (only the KwikPen formulation qualifies).

• Wegovy (all formulations, injectable and oral), COVERED under Bridge Program
• Zepbound KwikPen (tirzepatide), COVERED under Bridge Program
• Foundayo, COVERED under Bridge Program
• Ozempic (semaglutide, diabetes only), NOT covered for weight loss
• Mounjaro (tirzepatide, diabetes only), NOT covered for weight loss
• Zepbound single-dose pen or single-dose vial, NOT covered (KwikPen only qualifies)

Alternatives and Costs for Beneficiaries Outside Both Exceptions

If you do not have established cardiovascular disease and the Bridge Program does not yet apply (or has expired), GLP-1 drugs for weight loss are fully out-of-pocket. Wegovy lists at approximately $1,349 per month. Zepbound lists at approximately $1,029 per month. Manufacturer savings programs (Novo Nordisk and Eli Lilly both offer them) may reduce cost for commercially insured patients but are generally unavailable when the patient is on Medicare.

Alternatives worth considering: (1) switching to a Medicare Advantage plan that may add supplemental drug benefits in future plan years; (2) asking your physician whether a cardiovascular or diabetic indication applies and supports a covered prescription; (3) applying for the SNAP-related Extra Help program if your income is low, which helps with Part D costs generally; (4) for dual-eligible beneficiaries on Medicaid, checking whether your state covers GLP-1s for obesity under the Medicaid drug benefit.

Dual-Eligible Strategy: Does Medicaid Cover GLP-1s for Weight Loss?

About 12 million Americans are dual-eligible (enrolled in both Medicare and Medicaid). For dual-eligible beneficiaries, Medicaid is not bound by the Part D anti-obesity drug exclusion. State Medicaid programs set their own drug formularies. Several states already cover Wegovy or Zepbound for obesity management under their Medicaid programs. If your state covers these drugs through Medicaid, you may access them at Medicaid cost-sharing rates (often $0 to $4 per prescription) even if Medicare would not pay.

To check if you qualify for Medicaid alongside Medicare, use the eligibility screener. A single person with income below approximately $22,025 per year (138% of the 2026 FPL in expansion states, including the standard 5% MAGI disregard) may qualify for full Medicaid in the 40 states and DC that have expanded coverage. The 10 non-expansion states (AL, FL, GA, KS, MS, SC, TN, TX, WI, WY) have much lower income thresholds and may not cover this class of drug.

Does Medicare Part D cover Wegovy for weight loss in 2026?

Not by default. Part D cannot cover Wegovy for weight loss due to the MMA 2003 anti-obesity drug exclusion. However, two exceptions apply: (1) Wegovy is covered for adults with established cardiovascular disease who need MACE risk reduction; (2) the Medicare GLP-1 Bridge Program (July 1 to December 31, 2027) covers Wegovy at a flat $50/month copay for weight management regardless of CVD status. Outside these paths, you pay full list price of roughly $1,349 per month.

Is Ozempic covered by Medicare for weight loss?

No. Ozempic (semaglutide 0.5 to 2 mg) holds an FDA indication for type 2 diabetes only, not for chronic weight management. Medicare can cover Ozempic for beneficiaries with a type 2 diabetes diagnosis, but it cannot be prescribed or covered for weight loss alone under any current Medicare rule. Wegovy (semaglutide 2.4 mg) is the semaglutide formulation with a weight-management indication and the one that qualifies for the Bridge Program and CVD exception.

What is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a temporary federal program covering Wegovy, Zepbound (KwikPen), and Foundayo for chronic weight management from July 1, 2026 through December 31, 2027. The beneficiary copay is $50 per month flat. This copay does not count toward the 2026 Part D $2,100 out-of-pocket cap. The program applies to both standalone Part D plans and Medicare Advantage drug coverage. It expires automatically at the end of 2027 unless Congress extends it.

Does Medicare cover Zepbound for weight loss?

Under the Bridge Program (July 1, 2026 to December 31, 2027), Zepbound KwikPen (tirzepatide for weight management) is covered at $50 per month. Zepbound single-dose pen and single-dose vial formulations do not qualify for the Bridge Program. Outside the Bridge Program window, Zepbound for weight loss is not covered by Medicare. Mounjaro (also tirzepatide) has a diabetes-only indication and is not covered for weight loss under any exception.

How does the CVD exception work for Wegovy coverage on Medicare?

CMS clarified in March 2024 that Wegovy's FDA-approved cardiovascular indication (reducing MACE risk) takes the drug outside the Part D anti-obesity exclusion. To qualify, you must have established CVD (confirmed coronary artery disease, prior MI, or prior stroke), a BMI of at least 27, and a prescription written for MACE risk reduction rather than weight loss. Standard Part D cost-sharing applies. You will pay your plan's coinsurance or copay, subject to the $2,100 2026 OOP cap.

Will Medicare cover GLP-1 drugs for weight loss after 2027?

The Bridge Program expires December 31, 2027. After that date, the anti-obesity drug exclusion reasserts unless Congress passes legislation to repeal or modify Section 1927(d)(2)(A) of the Social Security Act. The TREATS Act and similar bills have been introduced but not passed as of May 2026. If Congress acts, CMS would need rulemaking time before new coverage begins. Monitor medicare.gov for any updates.

Does the Bridge Program $50 copay count toward my Part D out-of-pocket cap?

No. The $50 per month copay under the Medicare GLP-1 Bridge Program does not count toward the 2026 Part D out-of-pocket cap of $2,100. This is an explicit feature of the Bridge Program structure. If you also take other Part D drugs, those standard cost-sharing payments continue to count toward the $2,100 cap as normal.

Can dual-eligible Medicare-Medicaid beneficiaries get GLP-1s for free?

Possibly. Medicaid is not subject to the Part D anti-obesity drug exclusion, so state Medicaid programs can cover GLP-1s for obesity management. Several states already include Wegovy or Zepbound on their Medicaid formularies. Dual-eligible beneficiaries in those states may pay $0 to $4 per prescription. In expansion states, a single person earning below about $22,025 per year (138% of the 2026 FPL) may qualify for both Medicare and Medicaid. Use a screener to check your state and income eligibility.